Conversely, higher percentage of CD3+Tbet+ cells was detected in TLO from evanescent carcinoma sections (98.3 ± 2.86%), compared to their percentage in TLO from PIN (23.57 ± 12.48%, p = 0.0001), intermediate (37.41 ± 8.35%, p < 0.0001) and advanced prostate carcinoma patients (34.33 ± 8.35%, p = 0.0080) (Figure 8F). This evidence concerns the gene TBX21 and carcinoma.